[1] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer.2015; 136(5): E359-E386. doi: 10.1002/ijc.29210.
[2] Cumberbatch MGK, Jubber I, Black PC, et al. Epidemiology of bladder cancer: a systematic eeview and contemporary update of risk factors in 2018. Eur Urol. 2018; 74(6): 784-795. doi: 10.1016/j.eururo.2018. 09.001.
[3] Lerner SP. Bladder cancer: ASCO endorses EAU muscle-invasive bladder cancer guidelines. Nat Rev Urol. 2016; 13(8): 440-441. doi: 10.1038/nrurol.2016.114.
[4] Alfred Witjes J, Lebret T, Compérat EM, et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2017; 71(3): 462-475. doi: 10.1016/j.eururo.2016.06.020.
[5] Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001; 357(9255): 539-545. doi: 10.1016/S0140-6736 (00)04046-0.
[6] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5): 646-674. doi: 10.1016/j.cell.2011.02.013.
[7] Azab B, Bhatt VR, Phookan J, et al. Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol. 2012; 19(1): 217-224. doi: 10.1245/ s10434-011- 1814-0.
[8] Dell'Aquila E, Cremolini C, Zeppola T, et al. Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO. Ann Oncol. 2018; 29(4): 924-930. doi: 10.1093/annonc/mdy004.
[9] Ock CY, Nam AR, Lee J, et al. Prognostic implication of antitumor immunity measured by the neutrophil-lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer. Gastric Cancer. 2017; 20(2): 254-262. doi: 10.1007/s10120-016-0613-5.
[10] Wilson MJ, van Haaren M, Harlaar JJ, et al. Long-term prognostic value of preoperative anemia in patients with colorectal cancer: A systematic review and meta-analysis. Surg Oncol. 2017; 26(1): 96-104. doi: 10.1016/j. suronc.2017.01.005.
[11] Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010; 140(6): 883-899. doi: 10.1016/j.cell.2010.01.025.
[12] Choi Y, Kim JW, Nam KH, et al. Systemic inflammation is associated with the density of immune cells in the tumor microenvironment of gastric cancer. Gastric Cancer. 2017; 20(4): 602-611. doi: 10.1007/ s10120- 016- 0642-0.
[13] Leo C, Giaccia AJ, Denko NC. The hypoxic tumor microenvironment and gene expression. Semin Radiat Oncol. 2004; 14(3): 207-214. doi: 10.1016/j.semradonc.2004.04.007.
[14] McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013; 39(5): 534-540. doi: 10.1016/j.ctrv.2012.08.003.
[15] Masson-Lecomte A, Rava M, Real FX, et al. Inflammatory biomarkers and bladder cancer prognosis: a systematic review. Eur Urol. 2014; 66(6): 1078-1091. doi: 10.1016/j.eururo.2014.07.033.
[16] Lucca I, Jichlinski P, Shariat SF, et al. The neutrophil-to-lymphocyte ratio as a prognostic factor for patients with urothelial carcinoma of the bladder following radical cystectomy: validation and meta-analysis. Eur Urol Focus. 2016; 2(1): 79-85. doi:10.1016/j.euf.2015.03.001.
[17] D'Andrea D, Moschini M, Gust KM, et al. Lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio as biomarkers for predicting lymph node metastasis and survival in patients treated with radical cystectomy. J Surg Oncol. 2017; 115(4): 455-461. doi:10.1002/jso.24521.
[18] Peng D, Gong YQ, Hao H, et al. Preoperative prognostic nutritional index is a significant predictor of survival with bladder cancer after radical cystectomy: a retrospective study. BMC Cancer. 2017; 17(1): 391.doi: 10.1186/s12885-017-3372-8.
[19] Viers BR, Boorjian SA, Frank I, et al. Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy. Eur Urol. 2014; 66(6): 1157-1164. doi: 10.1016/ j.eururo. 2014.02. 042.
[20] Leibowitz-Amit R, Israel A, Gal M, et al. Association between the absolute baseline lymphocyte count and response to neoadjuvant platinum-based chemotherapy in muscle-invasive bladder cancer. Clin Oncol. 2016; 28(12): 790-796. doi: 10.1016/j.clon.2016.07.007.
[21] Black AJ, Zargar H, Zargar-Shoshtari K, et al. The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. Urol Oncol. 2020; 38(1): 3.e17-3.e27. doi:10.1016/ j.urolonc. 2019.09.023.
[22] Motomura T, Shirabe K, Mano Y, et al. Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol. 2013; 58(1): 58-64. doi: 10.1016/j.jhep.2012.08.017.
[23] Chen P, Zhao D, Li J, et al. Symbiotic macrophage-glioma cell interactions reveal synthetic lethality in PTEN-null glioma. Cancer Cell. 2019; 35(6): 868-884. doi: 10.1016/j.ccell.2019.05.003.
[24] Sell V, Ettala O, Montoya Perez I, et al. Symptoms and diagnostic delays in bladder cancer with high risk of recurrence: results from a prospective FinnBladder 9 trial. World J Urol. 2019; https://doi.org/10.1007/s00345-019-02841-4. Accessed 08 June 2019.
[25] Xia L, Guzzo TJ. Preoperative anemia and low hemoglobin level are associated with worse clinical outcomes in patients with bladder cancer undergoing radical cystectomy: a meta-analysis. Clin Genitourin Cancer. 2017; 15(2): 263-272. doi: 10.1016/j.clgc.2016.08.017.
[26] Grimm T, Buchner A, Schneevoigt B, et al. Impact of preoperative hemoglobin and CRP levels on cancer-specific survival in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: results of a single-center study. World J Urol. 2016; 34(5): 703-708. doi: 10.1007/s00345-015-1680-7.
[27] Bi H, Huang Y, Wang G, et al. Impact of body mass index and pretreatment hemoglobin level on prognosis following radical cystectomy for bladder cancer in males and females. Urol Int. 2019; 18:1-8. doi: 10.1159/000500561.
[28] Roy CN, Snyder PJ, Stephens-Shields AJ, et al. Association of testosterone levels with anemia in older men: a controlled clinical trial. JAMA Intern Med. 2017; 177(4): 480-490. doi: 10.1001/ jamainternmed. 2016. 9540.
[29] Gaspar BL, Sharma P, Das R. Anemia in malignancies: pathogenetic and diagnostic considerations. Hematology. 2015; 20(1): 18-25. doi: 10.1179/1607845414Y.0000000161.
[30] Fraenkel PG. Anemia of inflammation: a review. Med Clin North Am. 2017; 101(2): 285-296. doi: 10.1016/j.mcna.2016.09.005.